The overall goal of this NHLBI funded Program is to create and support a highly multidisciplinary team of expert chemists, biologists, engineers and physicians to develop and rapidly translate new nanotechnologies to better diagnose and treat heart, lung and blood disorders. The current team includes investigators from the Broad Institute, Massachusetts Institute of Technology (MIT), Harvard Faculty of Arts and Sciences (FAS), Harvard Medical School (HMS), Massachusetts General Hospital (MGH) and Brigham and Women's Hospital (BWH). Specific applications of nanotechnology in this application include molecular imaging and sensing, drug delivery, targeted therapies and tissue repair. Powerful chemical biology approaches are being used to functionalize nanomaterials and to test their biosafety at unprecedented throughputs .